Yumanity Therapeutics, a leader in the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced that it has entered into a strategic research collaboration and license agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) focused on accelerating the development of new treatments for neurodegenerative diseases.